PapersPMID:36074799
The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“The authors found a reduction in MRI-PDFF between weeks 0 and 24 in the oligonol group; however, the change was not different from the placebo group.”
- Study
- RCT
- Duration
- 6 months
- Population
- Adults with non-alcoholic fatty liver disease (MRI-PDFF 11% or more)
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adult patients with NAFLD defined by MRI-PDFF of 11% or more; Oligonol, an oligomerized-polyphenol from Litchi chinensis extract (abstract only)
- Participants
- 40
- Comparator
- placebo
- Duration
- 168 days
- Endpoints measured
- 4